Table 4.

Experimental design of investigated models of hepatocarcinogenesis.

Treatment Procedure	Sacrifice Time Point	Gefitinib Administration	N		Sacrifice Time Point	Gefitinib Administration	N
Experimental groups				Control groups
PTx (male)	3 weeks	-	8	male	3 weeks	-	10
	3 weeks	2 weeks HD	12		3 weeks	2 weeks HD	10
	6 months	-	10		3 months	-	15
	6 months	2 weeks HD	14		3 months	2 weeks HD	15
	6 months	3 months LD	12		3 months	3 months LD	15
	12 months	-	34		6 months	-	26
	12 months	2 weeks HD	17		6 months	2 weeks HD	25
	12 months	3 months LD	17		6 months	3 months LD	25
	24 months	-	19		12 months	-	11
	24 months	9 months LD	10		12 months	2 weeks HD	10
					12 months	3 months LD	10
TTx (male)	3 months	-	15		24 months	-	19
	3 months	2 weeks HD	15		24 months	9 months LD	24
	12 months	-	15
	12 months	2 weeks HD	14	female	3 months	-	10
	12 months	3 months LD	13		3 months	2 weeks HD	10
	24 months	-	15		12 months	-	14
	24 months	9 months LD	15		12 months	2 weeks HD	9
					12 months	3 months LD	9
OTx (female)	3 months	-	15		24 months	-	21
	3 months	2 weeks HD	15		24 months	9 months LD	17
	12 months	-	15
	12 months	2 weeks HD	16
	12 months	3 months LD	16
	24 months	-	20
	24 months	9 months LD	21
NNM	3 months	-	15
	3 months	2 weeks HD	15
	3 months	3 months LD	15
	6 months	-	15
	6 months	2 weeks HD	15
	6 months	3 months LD	15

Overview of all investigated experimental and control groups in short (3 weeks, and 3 and 6 months) and long term investigations (12 and 24 months) after intraportal transplantation of pancreatic islets (PTx), ovarian fragments (OTx) or thyroid follicles (TTx) or administration of N-Nitrosomorpholine (NNM) at different sacrifice time points (time after transplantation or beginning of NNM administration) and with or without administration of gefitinib (HD, high doses of 20 mg/kg body weight, LD, low doses of 10 mg/kg body weight) as indicated. N number of animals in respective groups.